| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. | Director | Common Stock, par value $0.01 per share | 644K | May 12, 2025 | Direct | ||
| Apimeds Pharmaceuticals US, Inc. | Director | Stock Option (right to buy) | 10K | Nov 11, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | Nov 11, 2025 | 1 | $0 | 4 | Nov 13, 2025 | Director |
| APUS | Apimeds Pharmaceuticals US, Inc. | Oct 15, 2025 | 1 | $0 | 4 | Oct 17, 2025 | Director |
| APUS | Apimeds Pharmaceuticals US, Inc. | May 16, 2025 | 1 | $0 | 4 | May 20, 2025 | Director |
| APUS | Apimeds Pharmaceuticals US, Inc. | May 12, 2025 | 1 | $56.7K | 4 | May 14, 2025 | Director |
| APUS | Apimeds Pharmaceuticals US, Inc. | Mar 4, 2025 | 0 | $0 | 3 | May 8, 2025 | Director |